Talicia Holdings

Talicia Holdings Inc. is a specialty biopharmaceutical company established in October 2025 as a strategic joint venture between RedHill Biopharma and Cumberland Pharmaceuticals. The entity was formed to hold the global rights and manage the commercialization of Talicia, an FDA-approved all-in-one oral capsule for the treatment of Helicobacter pylori infection in adults. RedHill retains a 70% ownership stake and oversees manufacturing and regulatory affairs, while Cumberland holds a 30% stake and manages U.S. sales and distribution through its national sales organization. Talicia is recognized as a first-line therapy in clinical guidelines and is the only rifabutin-based H. pylori treatment approved by the FDA. The company is focused on expanding Talicia's market presence in the U.S. and internationally, including recent entries into the Middle East and planned expansion into the United Kingdom.